Universal STAR-T Cell Injection

Universal STAR-T Cell Injection is an allogeneic (off-the-shelf) cell therapy being developed for the treatment of multiple sclerosis (MS), including progressive and relapsing-remitting forms. The therapy utilizes Synthetic T-cell Antigen Receptor (STAR) technology, which involves engineering T cells to express a synthetic receptor that fuses antibody-derived antigen-recognition domains with the constant regions of a natural T-cell receptor (TCR). This design is intended to provide more physiological signaling and higher sensitivity than traditional Chimeric Antigen Receptors (CARs). The "universal" aspect of the therapy indicates that the cells are derived from healthy donors and gene-edited to prevent graft-versus-host disease (GvHD) and rejection by the recipient's immune system, allowing for immediate use without patient-specific manufacturing. The therapy targets B-cell populations (specifically CD19) to eliminate the cells responsible for the autoimmune response in MS. It is currently in Phase I clinical development under the leadership of Daishi Tian at Tianjin Medical University.

Other names

Universal STAR-T Cell